Clinical trials: Community Acquired Pneumonia, Severe
Severe Community-Acquired Pneumonia (sCAP), Elderly Infection
ESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients
The ESCAPE 10 study is a multinational, retrospective, observational cohort study that aims to investigate the epidemiology and outcome determinants of severe community-acquired pneumonia (sCAP) in elderly patients (≥65 years).
- Conditions
- Severe Community-Acquired Pneumonia (sCAP), Elderly Infection, Community-Acquired Infections, Health Care Quality, Access, and Evaluation
- Trial name
- ESCAPE10 (NCT07070284)
- Where
- 18 sites in Croatia, France and 4 more
- Volunteers
- 500 people
- Sponsor
- Joan Sabater-Riera
Community-acquired Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)
The main objective of the trial is to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in hospitalized subjects with sCAP on invasive mechanical…
- Trial name
- ESsCAPE (NCT05722938)
- Testing
- Trimodulin
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 590 people
- Sponsor
- Biotest
Pneumonia, Pneumonia - Bacterial
Derivation and Validation of the Risk Evaluation Score for Pneumonia Involving Resistant Entities (RESPIRE)
This is a single-center, non-profit observational study with two sequential phases: an initial retrospective phase followed by a prospective phase. Patients were enrolled during two consecutive, non-overlapping periods.
- Conditions
- Pneumonia, Pneumonia - Bacterial, Multi Drug Resistant, Multi Drug Resistant Organisms
- Trial name
- RESPIRE (NCT07425561)
- Testing
- RESPIRE score
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Pneumonia, Sepsis
Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization.
- Conditions
- Pneumonia, Sepsis, Shock, Septic
- Trial name
- PROGRESSCOMORB (NCT05688774)
- Where
- 10 sites in Germany
- Volunteers
- 300 people
- Sponsor
- Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Community Acquired Pneumonia
Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
The purpose of this study is to prove the clinical and bacteriological non-inferiority of ampicillin/amoxicillin versus moxifloxacin in hospitalized patients with non-severe community-acquired pneumonia.
- Trial name
- PENCAP (NCT00887276)
- Testing
- Moxifloxacin, Ampicillin;Amoxicillin
- Where
- 8 sites in Germany
- Volunteers
- 290 people
- Sponsor
- University of Ulm
Respiratory Distress Syndrome, Acute, Severe Community-Acquired Pneumonia
Multimodal Database and Large Language Model for ARDS
The goal of this observational study is to integrate existing clinical cohorts from the research team to establish dedicated cohorts for ARDS and high-risk ARDS patients (primarily SCAP patients), then systematically collect…
- Trial name
- NCT06973733
- Testing
- Clinical data and biospecimen collection
- Volunteers
- 6,500 people
- Sponsor
- China-Japan Friendship Hospital
Pneumonia, Bacterial
Blinded Efficacy and Safety Study of CAL02 IV Plus SOC in Subjects With Severe Community-Acquired Bacterial Pneumonia
This is a placebo-controlled study to evaluate the addition of CAL02 to standard of care in treating hospitalized subjects diagnosed with severe community acquired bacterial pneumonia (SCABP) requiring critical care measures
- Trial name
- NCT05776004
- Testing
- CAL02
- Where
- 90 sites in United States, Argentina and 17 more
- Volunteers
- 276 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Pneumonia, Bacterial, Community-Acquired Infections
A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia
The purpose of this study is to evaluate the safety and tolerability of doripenem compared to cefepime in children hospitalized with pneumonia.
- Conditions
- Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
- Trial name
- NCT01110421
- Testing
- Cefepime, Doripenem, Amoxicillin/clavulanate potassium
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 7 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Community Acquired Pneumonia, Respiration Failure
A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia
Severe community acquired pneumonia is common and associated with high mortality. Conventional microbiological diagnostics identify pathogens in approximately half of cases, which is inadequate for both clinical and…
- Conditions
- Community Acquired Pneumonia, Respiration Failure, Pneumonia
- Trial name
- S-CAP (NCT02963142)
- Where
- United Kingdom
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pneumonia, Sepsis
Study of Progression of Community Acquired Pneumonia in the Hospital
Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization.
- Conditions
- Pneumonia, Sepsis, Shock, Septic
- Trial name
- PROGRESS (NCT02782013)
- Where
- 64 sites in Austria, Germany
- Volunteers
- 2,309 people
- Sponsor
- Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
Community-acquired Pneumonia
Clinical Efficacy of Amoxicillin Given Twice or Three Times a Day Among Children With Non-severe Pneumonia
The purpose of the study is to compare the clinical efficacy of amoxicillin given twice or three times a day to children with non-severe community-acquired pneumonia.
- Trial name
- PNEUMOPACEf (NCT01200706)
- Testing
- Amoxicillin
- Where
- Brazil
- Volunteers
- 820 people
- Sponsor
- Federal University of Bahia
Community Acquired Pneumonia
Safety and Efficacy Study of BT086 to Evaluate Adjunctive Therapy in sCAP
The purpose of this study is to determine whether the adjunctive therapy to standard antibiotic treatment of BT086 is safe and effective of decreasing the days patients require endotracheal ventilation due to Severe…
- Trial name
- CIGMA (NCT01420744)
- Testing
- BT086, 1% Human Albumin infusion
- Where
- 36 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Biotest
Psittacosis
Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults
Severe community-acquired pneumonia caused by psittacosis is a form of atypical-pathogen community-acquired pneumonia that often requires critical care management.
- Trial name
- NCT07352865
- Testing
- Saline (0.9%, sterile, for infusion), low dose Methylprednisolone, Moderate dose Methylprednisolone
- Volunteers
- 100 people
- Sponsor
- Qingyuan Zhan
Community-Acquired Pneumonia (CAP), Pneumonia
Clinical Impact of Rapid Molecular Testing for Pathogens in Patients With Severe Acute Respiratory Illness : A Pragmatic Trial
Community-acquired pneumonia (CAP) is among the most common reasons for emergency department (ED) visits. A clear understanding of the likely pathogens is essential for the rapid institution of adequate antimicrobial therapy.
- Trial name
- CIRT-RMT-SARI (NCT06605352)
- Testing
- The BIOFIRE®FILMARRAY® Pneumonia Panel
- Where
- Taiwan
- Volunteers
- 800 people
- Sponsor
- National Taiwan University Clinical Trial Center
Community-acquired Pneumonia
Multicenter Epidemiologic Study of Severe Community Acquired Pneumonia in China
This study is aimed to understand the clinical characteristics, etiology and resistance phenotype of major pathogens of SCAP in China through multicenter and prospective investigation.
- Trial name
- NCT03728816
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Ruijin Hospital
Community Acquired Pneumonia, Hospital Acquired Pneumonia
The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia
The purpose of the study is to determine if the clinical course of pneumonia is more severe when both, bacterial and viral pathogens are find as possible causative agent and how does it affect treatment.
- Conditions
- Community Acquired Pneumonia, Hospital Acquired Pneumonia, Ventilator Associated Pneumonia
- Trial name
- SCAHAVAP (NCT02203110)
- Where
- Slovenia
- Volunteers
- 150 people
- Sponsor
- University Medical Centre Ljubljana
Community-acquired Pneumonia, Critical Illness
Point-of-Care Multiplex for Adult Patients With Severe Community-acquired Pneumonia
Clinical Impact on Point-of-Care Multiplex PCR Testing for Critically Ill Adult Patients With Community-acquired Pneumonia - A cluster randomization study in ICU units within one medical center.
- Trial name
- NCT04835818
- Testing
- Provide the panel report to the primary care physician
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Severe Pneumonia
Research on the Treatment of Severe Community-acquired Pneumonia in Children
The need for glucocorticoid therapy in children with severe community-acquired pneumonia in the acute phase of the disease remains unclear.
- Trial name
- NCT05768204
- Testing
- Prednisolone Acetate
- Where
- 3 sites in China
- Volunteers
- 160 people
- Sponsor
- Baoping XU
Community Acquired Pneumonia
Short Duration Treatment of Non-severe Community Acquired Pneumonia
To investigate the non inferiority of a short lasting antibiotic treatment (3 days) when compared to a long lasting antibiotic treatment (8 days), at Day 15 after the beginning of treatment in terms of clinical efficacy, in…
- Trial name
- PTC (NCT01963442)
- Testing
- Chest X-ray, blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry, Augmentin
- Where
- 20 sites in France
- Volunteers
- 310 people
- Sponsor
- Versailles Hospital